You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
IQvia, the lead investor in this round, will work with BC Platforms to integrate genomic and clinical data in a secure environment to support biomedical research.
Now a subsidiary of IQvia, NLP vendor Linguamatics also is looking to help precision medicine providers and pharma researchers with phenotype-genotype matching.
The new IQvia E360 Genomics build includes a "privacy-preserving" database system and will soon have analytic tools to support genotype-phenotype research.
CRO and analytics giant IQvia, the product of the IMS Health-Quintiles merger, quietly purchased UK-based bioinformatics company Linguamatics a month ago.
The analytics firm formerly known as Quintiles IMS will offer researchers secure access to Genomics England's de-identified databases in pursuit of precision medicine.
Under the terms of the agreement, Q2 Solutions will develop companion diagnostics on Illumina's MiSeqDx instrument.
In the second quarter, Quest reported revenues of $1.93 billion and estimated 2015 revenues will be between $7.49 billion and $7.57 billion.
The firms aim to establish the second largest lab services firm in the world to aid drugmakers with clinical trials.
The joint venture – of which Quintiles will own 60 percent and Quest will own 40 percent – is poised to be the second largest central laboratory services firm in the world.
NEW YORK (GenomeWeb) – Roche subsidiary Ventana Medical Systems has signed an agreement with contract research organization Quintiles to offer companion diagnostic testing services to drug developers performing early stage oncology studies in China.
New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.
A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.
Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.
In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.